COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,676 Articles (22,913 medRxiv, 8,763 bioRxiv)

Most recent first Previous |  Page 2687: Articles 26861-26870  | Next

Prevention of household transmission crucial to stop the catastrophic spread of COVID-19 in cities
Gutierrez Brizuela, N., Gutierrez Pulido, H., Roosa, K., Garcia Chan, N., Hernandez-Bello, J., Munoz-Valle, J. F., Macedo-Ojeda, G., Lopez-Chavez, J. A., Gonzalez Estevez, G., Villanueva Lomeli, R., Chowell, G.
10.1101/2020.06.05.20123711 — Posted: 2020-06-07
Belief of Previous COVID-19 Infection and Unclear Government Policy are Associated with Reduced Willingness to Participate in App-Based Contact Tracing: A UK-Wide Observational Study of 13,000 Patients
Bachtiger, P., Adamson, A., Quint, J. K., Peters, N. S.
10.1101/2020.06.03.20120337 — Posted: 2020-06-06
Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries
Lou, Y., Zhao, W., Wei, H., Chu, M., Chao, R., Yao, H., Su, J., Li, Y., Li, X., Cao, Y., Feng, Y., Wang, P., Xia, Y., Shang, Y., Li, F., Ge, P., Zhang, X., Gao, W., Du, B., Liang, T., Qiu, Y., Liu, M.
10.1101/2020.06.06.137513 — Posted: 2020-06-06
ScRNA-seq discover cell cluster change under OAB: ACE2 expression reveal possible alternation of 2019-nCoV infectious pathway
Xiang, B., Hu, X., Li, H., Ma, L., Zhou, H., Wei, L., Fan, J., Zheng, J.
10.1101/2020.06.05.137380 — Posted: 2020-06-06
Protein covariance networks reveal interactions important to the emergence of SARS coronaviruses as human pathogens
Robins, W. P., Mekalanos, J. J.
10.1101/2020.06.05.136887 — Posted: 2020-06-06
Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells
Miersch, S., Ustav, M., Li, Z., Case, J. B., Ganaie, S., Matusali, G., Colavita, F., Lapa, D., Capobianchi, M. R., Novelli, G., Gupta, J. B., Jain, S., Pandolfi, P. P., Diamond, M. S., Amarasinghe, G., Rini, J. M., Sidhu, S. S.
10.1101/2020.06.05.137349 — Posted: 2020-06-06
Human mobility and poverty as key factors in strategies against COVID-19
Yechezkel, M., Weiss, A., Rejwan, I., Shahmoon, E., Ben Gal, S., Yamin, D.
10.1101/2020.06.04.20112417 — Posted: 2020-06-06
Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19
Rhodes, N. J., Dairem, A., Moore, W., Shah, A., Postelnick, M. J., Badowski, M. E., Michienzi, S. M., Borkowski, J. L., Polisetty, R. S., Fong, K., Spivek, E. S., Beardsley, J. R., Hale, C. M., Pallotta, A. M., Srinivas, P., Schulz, L. T.
10.1101/2020.06.03.20121558 — Posted: 2020-06-06
Cremation based estimates suggest significant under- and delayed reporting of COVID-19 epidemic data in Wuhan and China
He, M., Li, L., Dehner, L. P., Dunn, L.
10.1101/2020.05.28.20116012 — Posted: 2020-06-06 Discussion: Onsite
Class I HLA allele restricted antigenic coverage for Spike and N proteins is associated with divergent outcomes for COVID-19
Pretti, M. A. M., Galvani, R. G., Vieira, G. F., Bonomo, A., Bonamino, M. H., Boroni, M.
10.1101/2020.06.03.20121301 — Posted: 2020-06-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).